

## CPRD Research Data Governance (RDG) Application Template

**ALL APPLICATIONS MUST BE COMPLETED AND SUBMITTED VIA THE CPRD ELECTRONIC RESEARCH APPLICATION PORTAL (eRAP)**

[www.erap.cprd.com](http://www.erap.cprd.com)

An eRAP guide for users can be found here [www.cprd.com/cprd-erap-guide-users](http://www.cprd.com/cprd-erap-guide-users)

Applicants may use this template offline to prepare their research application, prior to submission on eRAP. Applicants must also read CPRD's Research Data Governance (RDG) Guidance on how to complete their application found on the eRAP landing page under 'Related resources' ( [www.erap.cprd.com](http://www.erap.cprd.com) )

### PART 1: APPLICATION FORM

GENERAL INFORMATION ABOUT THE PROPOSED RESEARCH STUDY			
1. Study Title (max. 255 characters)			
2. Research Area (place 'X' in all boxes that apply)			
Drug Safety		Economics	
Drug Utilisation		Pharmacoeconomics	
Drug Effectiveness		Pharmacoepidemiology	
Disease Epidemiology		Methodological	
Health Services Delivery			
3. Does this protocol describe an observational study using purely CPRD data?			
Yes	<input type="checkbox"/>	No	<input type="checkbox"/>
4. Does this protocol involve requesting any additional information from GPs, or contact with patients?			
Yes	<input type="checkbox"/>	No	<input type="checkbox"/>
If yes, provide the reference number:			
5. Chief Investigator			

Title:	
Full name:	
Job title:	
Affiliation/organisation:	
Email address:	
CV Number (if applicable):	
Will this person be analysing the data? (Y/N)	

**6. Corresponding Applicant**

Title:	
Full name:	
Job title:	
Affiliation/organisation:	
Email address:	
CV Number (if applicable):	
Will this person be analysing the data? (Y/N)	

**7. List of all investigators/collaborators**

Title:	
Full name:	
Job title:	
Affiliation/organisation:	
Email address:	
CV Number (if applicable):	
Will this person be analysing the data? (Y/N)	

**ACCESS TO THE DATA**

**8. Sponsor of the study**

Institution/Organisation:	
Address:	

**9. Funding source for the study**

Same as Sponsor?	Yes		No	
Institution/Organisation:				
Address:				

**10. Institution conducting the research**

Same as Sponsor?	Yes		No	
Institution/Organisation:				
Address:				

**11. Data Access Arrangements**

Indicate with an 'X' the method that will be used to access the data for this study:

Study-specific Dataset Agreement	
Institutional Multi-study Licence	
Institution Name	
Institution Address	

Will the dataset be extracted by CPRD?

Yes	<input type="checkbox"/>	No	<input type="checkbox"/>
-----	--------------------------	----	--------------------------

If **yes**, provide the reference number:

Are multiple data deliveries required for this research?

Yes	<input type="checkbox"/>	No	<input type="checkbox"/>
-----	--------------------------	----	--------------------------

If **yes**, provide the reference number:

**12. Data Processor(s):**

Processing	<input type="checkbox"/>
Accessing	<input type="checkbox"/>
Storing	<input type="checkbox"/>
Processing area (UK/EEA/Worldwide)	<input type="text"/>
Organisation name	<input type="text"/>
Organisation address	<input type="text"/>

Processing	<input type="checkbox"/>
Accessing	<input type="checkbox"/>
Storing	<input type="checkbox"/>
Processing area (UK/EEA/Worldwide)	<input type="text"/>
Organisation name	<input type="text"/>
Organisation address	<input type="text"/>

**INFORMATION ON DATA**

**13. Primary care data** (place 'X' in all boxes that apply)

CPRD GOLD	<input type="checkbox"/>	CPRD Aurum	<input type="checkbox"/>
-----------	--------------------------	------------	--------------------------

Reference number (if applicable):

**14. Please select any linked data or data products being requested**

**Patient Level Data** (place 'X' in all boxes that apply)

ONS Death Registration Data	<input type="checkbox"/>	NCRAS Tumour/ Treatment data	<input type="checkbox"/>
HES Admitted Patient Care	<input type="checkbox"/>	NCRAS Systemic Anti-Cancer Treatment (SACT) data	<input type="checkbox"/>
HES Outpatient	<input type="checkbox"/>	NCRAS National Radiotherapy Dataset (RTDS) data	<input type="checkbox"/>
HES Accident and Emergency	<input type="checkbox"/>	Second Generation Surveillance System (SGSS, COVID-19)	<input type="checkbox"/>
HES Diagnostic Imaging Dataset	<input type="checkbox"/>	COVID-19 Hospitalisations in England Surveillance System (CHESS)	<input type="checkbox"/>
CPRD Mother Baby Link	<input type="checkbox"/>	CPRD Ethnicity Record	<input type="checkbox"/>
Pregnancy Register	<input type="checkbox"/>		<input type="checkbox"/>

**Area Level Data** (place 'X' in one Practice / Patient level box that may apply)

Practice level (UK)		Patient level (England only)	
Practice Level Index of Multiple Deprivation		Patient Level Index of Multiple Deprivation	
Practice Level Index of Multiple Deprivation Domains		Patient Level Index of Multiple Deprivation Domains	
Practice Level Carstairs Index for 2011 Census (Excluding Northern Ireland)		Patient Level Carstairs Index for 2011 Census	
2011 Rural-Urban Classification at LSOA level		2011 Rural-Urban Classification at LSOA level	
		Patient Level Townsend Score	

Reference / Protocol number (where applicable):

**15. Are you requesting linkage to a dataset not listed above?**

Yes	<input type="checkbox"/>	No	<input type="checkbox"/>
-----	--------------------------	----	--------------------------

If yes, provide the Non-Standard Linkage reference number:

**16. Does any person named in this application already have access to any of these data in a patient identifiable form, or associated with an identifiable patient index?**

Yes	<input type="checkbox"/>	No	<input type="checkbox"/>
-----	--------------------------	----	--------------------------

If yes, provide further details:

## PART 2: PROTOCOL INFORMATION

Applicants must complete all sections
<b>Study Title</b> <i>(max. 255 characters)</i>
<b>Lay Summary</b> <i>(max. 250 words)</i>
<b>Technical Summary</b> <i>(max. 300 words)</i>
<b>Outcomes to be Measured</b> <i>(max. 100 words)</i>
<b>Objectives, Specific Aims and Rationale</b> <i>(max. 250 words)</i>
<b>Study Background</b> <i>(max. 250 words)</i>
<b>Study Type</b> <i>(max. 50 words)</i>
<b>Study Design</b> <i>(max. 100 words)</i>
<b>Feasibility counts</b> <i>(max. 200 words)</i>
<b>Sample size considerations</b> <i>(max. 200 words)</i>
<b>Planned use of linked data (if applicable)</b> <i>(max. 200 words)</i>
<b>Definition of the Study population</b> <i>(max. 250 words)</i>
<b>Selection of comparison group(s) or controls</b> <i>(max. 250 words)</i>
<b>Exposures, Outcomes and Covariates</b> <i>(max. 1000 words)</i>
<b>Data/ Statistical Analysis</b> <i>(max. 1000 words)</i>
<b>Plan for addressing confounding</b> <i>(max. 200 words)</i>
<b>Plans for addressing missing data</b> <i>(max. 200 words)</i>
<b>Patient or user group involvement</b> <i>(max. 150 words)</i>
<b>Plans for disseminating and communicating study results</b> <i>(max.150 words)</i>
<b>Conflict of interest statement</b> <i>(max.150 words)</i>
<b>Limitations of the study design, data sources, and analytic methods</b> <i>(max. 200 words)</i>
<b>References</b> <i>(max. 20 references)</i>
<b>List of Appendices</b> <i>(max. of 5 files)</i>
<b>Grant ID (optional)</b> <i>(max. 255 characters)</i>